Nathan Vastesaeger
Overview
Explore the profile of Nathan Vastesaeger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vanier A, Smolen J, Allaart C, van Vollenhoven R, Verschueren P, Vastesaeger N, et al.
Rheumatology (Oxford)
. 2019 Nov;
59(8):1842-1852.
PMID: 31722413
Objective: In early RA, some patients exhibit rapid radiographic progression (RRP) after one year, associated with poor functional prognosis. Matrices predicting this risk have been proposed, lacking precision or inadequately...
2.
Claudepierre P, Van den Bosch F, Sarzi-Puttini P, Vastesaeger N, Govoni M, Kachroo S
Int J Rheum Dis
. 2019 Apr;
22(6):995-1001.
PMID: 30989813
Aim: We evaluated the effects of anti-tumor necrosis factor (TNF) agents on health economics in ankylosing spondylitis (AS) patients. Methods: QUality of Life as Outcomes and its VAriation with DIsease...
3.
Van den Bosch F, Flipo R, Braun J, Vastesaeger N, Kachroo S, Govoni M
Clin Exp Rheumatol
. 2018 Aug;
37(2):199-207.
PMID: 30148434
Objectives: The QUO VADIS study evaluated disease activity and health-related quality-of-life (HRQoL) in ankylosing spondylitis (AS) patients treated with golimumab (GLM) or infliximab (IFX, originator) during routine clinical care. Methods:...
4.
Durez P, Pavelka K, Lazaro M, Garcia-Kutzbach A, Moots R, Amital H, et al.
Clin Rheumatol
. 2018 May;
37(7):2017-2018.
PMID: 29752584
The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of...
5.
Varkas G, Vastesaeger N, Cypers H, Colman R, Renson T, Van Praet L, et al.
Arthritis Rheumatol
. 2018 May;
70(10):1588-1596.
PMID: 29740978
Objective: To determine the link between extraarticular manifestations (EAMs) and baseline characteristics in patients with axial spondyloarthritis (SpA), and to define their potentially differential prognostic value in 2 large, independent...
6.
Durez P, Pavelka K, Lazaro M, Garcia-Kutzbach A, Moots R, Amital H, et al.
Clin Rheumatol
. 2018 Apr;
37(5):1417-1420.
PMID: 29611083
GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-naïve patients with active rheumatoid arthritis (RA). The objective of this post...
7.
Sieper J, Rudwaleit M, Lenaerts J, Wollenhaupt J, Myasoutova L, Park S, et al.
Rheumatology (Oxford)
. 2016 Jul;
55(11):1946-1953.
PMID: 27411482
Objectives: To evaluate partial remission during treatment with infliximab (IFX) + naproxen (NPX) vs NPX alone in patients from the two subgroups of SpA and explore baseline predictors of partial...
8.
Vastesaeger N, Garcia Kutzbach A, Amital H, Pavelka K, Lazaro M, Moots R, et al.
Rheumatology (Oxford)
. 2016 Apr;
55(8):1466-76.
PMID: 27114562
Objective: To create a tool to predict probability of remission and low disease activity (LDA) in patients with RA being considered for anti-TNF treatment in clinical practice. Methods: We analysed...
9.
Vastesaeger N, Fautrel B, Smolen J
Arthritis Res Ther
. 2015 Jun;
17:166.
PMID: 26091916
No abstract available.
10.
Schulze-Koops H, Giacomelli R, Samborski W, Rednic S, Herold M, Yao R, et al.
Clin Exp Rheumatol
. 2015 Feb;
33(2):201-8.
PMID: 25664404
Objectives: To evaluate factors influencing injection patterns and patient evaluations of an autoinjector device in biologic-naïve patients beginning golimumab (GLM) treatment. Methods: GO-MORE was an open-label, multinational, prospective study in...